The estimated Net Worth of Dipti Amin is at least 30.3 千$ dollars as of 28 March 2022. Dipti Amin owns over 35,000 units of Lineage Cell Therapeutics Inc stock worth over 30,282$ and over the last 4 years Dipti sold LCTX stock worth over 0$.
Sign up
Dipti Amin LCTX stock SEC Form 4 insiders trading
Dipti has made over 1 trades of the Lineage Cell Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Dipti bought 35,000 units of LCTX stock worth 57,050$ on 28 March 2022.
The largest trade Dipti's ever made was buying 35,000 units of Lineage Cell Therapeutics Inc stock on 28 March 2022 worth over 57,050$. On average, Dipti trades about 5,833 units every 0 days since 2021. As of 28 March 2022 Dipti still owns at least 35,000 units of Lineage Cell Therapeutics Inc stock.
You can see the complete history of Dipti Amin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Dipti Amin's mailing address?
Dipti's mailing address filed with the SEC is C/O LINEAGE CELL THERAPEUTICS, 2173 SALK AVENUE, SUITE 200, CARLSBAD, CA, 92008.
Insiders trading at Lineage Cell Therapeutics Inc
Over the last 5 years, insiders at Lineage Cell Therapeutics Inc have traded over 2,612,743$ worth of Lineage Cell Therapeutics Inc stock and bought 7,879,334 units worth 8,569,904$ . The most active insiders traders include Partners, L.P.Broadwood Cap...、Alfred D Kingsley、Brian M Culley. On average, Lineage Cell Therapeutics Inc executives and independent directors trade stock every 49 days with the average trade being worth of 212,992$. The most recent stock trade was executed by Jill Ann Howe on 16 August 2024, trading 10,500 units of LCTX stock currently worth 9,345$.
What does Lineage Cell Therapeutics Inc do?
biotime, inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world's premier collection of pluripotent cell assets. the foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.
What does Lineage Cell Therapeutics Inc's logo look like?
Complete history of Dipti Amin stock trades at Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics Inc executives and stock owners
Lineage Cell Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Brandi Roberts,
Chief Financial Officer -
Brian M. Culley M.A., M.B.A.,
CEO, Pres & Director -
Brian Culley,
Chief Executive Officer, Director -
Chase Leavitt,
General Counsel and Corporate Secretary -
Brandi L. Roberts,
Consultant -
Angus Russell,
Independent Director -
Michael Mulroy,
Independent Director -
Stephen Farrell,
Independent Director -
Neal Bradsher,
Independent Director -
Don Bailey,
Independent Director -
Deborah Andrews,
Independent Director -
Gary Hogge,
Senior Vice President of Clinical & Medical Affairs -
Alfred Kingsley,
Chairman of the Board -
Alexandra Hernandez,
Sr. Director of Fin. & Controller -
Dr. Rami Skaliter,
Chief Exec. Officer of Cell Cure Neurosciences Ltd. -
William Annett,
Pres & CEO of OncoCyte Corp. -
Dr. Gary S. Hogge D.V.M., Dvm, Ms, Ph.D.,
Sr. VP of Clinical & Medical Affairs -
Dr. François Binette M.Sc., Ph.D.,
Sr. VP & Global Head of R&D -
George A. Samuel III, J.D.,
Gen. Counsel & Company Sec. -
Ioana C. Hone,
Director of Investor Relations -
Kevin L. Cook,
Chief Financial Officer -
George A. Iii Samuel,
General Counsel/Secretary -
Anula Jayasuriya,
-
Dipti Amin,
-
Neal C Bradsher,
Director -
Alexandra Hernandez,
Sr Director Finance/Controller -
Kevin Leon Cook,
Chief Financial Officer -
Jill Ann Howe,
Chief Financial Officer